X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
medicine, general & internal (2) 2
abridged index medicus (1) 1
adolescent (1) 1
adrenergic alpha-1 receptor antagonists - therapeutic use (1) 1
adult (1) 1
adults (1) 1
aged (1) 1
analysis (1) 1
article (1) 1
breast (1) 1
breast cancer (1) 1
calcium channel blockers - therapeutic use (1) 1
cancer therapies (1) 1
cardiac events (1) 1
chemotherapy (1) 1
clinical trials (1) 1
colic (1) 1
colic - drug therapy (1) 1
colic - etiology (1) 1
double-blind method (1) 1
drug (1) 1
emergency medical care (1) 1
emergency-department visits (1) 1
erbb-2 protein (1) 1
facilitate (1) 1
female (1) 1
follow-up (1) 1
herceptin (1) 1
hospitals (1) 1
humans (1) 1
hypotheses (1) 1
index medicus (1) 1
internal medicine (1) 1
kidney stones (1) 1
lithotripsy (1) 1
male (1) 1
management (1) 1
medical colleges (1) 1
medical research (1) 1
medical treatment (1) 1
medicine (1) 1
middle aged (1) 1
motivation (1) 1
multicenter (1) 1
neoadjuvant pertuzumab (1) 1
nifedipine (1) 1
nifedipine - therapeutic use (1) 1
open-label (1) 1
pharmaceuticals (1) 1
plus (1) 1
r medicine (1) 1
randomization (1) 1
recommendations (1) 1
research & development--r&d (1) 1
smooth muscle (1) 1
stone passage (1) 1
studies (1) 1
sulfonamides - therapeutic use (1) 1
survival (1) 1
technology assessment (1) 1
therapy (1) 1
toxicity (1) 1
trastuzumab (1) 1
treatment outcome (1) 1
united kingdom (1) 1
ureteral calculi - complications (1) 1
ureteral calculi - drug therapy (1) 1
ureteral calculi - pathology (1) 1
ureteral diseases - drug therapy (1) 1
ureteral diseases - etiology (1) 1
urological agents - therapeutic use (1) 1
young adult (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet, The, ISSN 0140-6736, 2015, Volume 386, Issue 9991, pp. 341 - 349
Journal Article
by Earl, Helena and Earl, Helena M and Hiller, Louise and Vallier, Anne-Laure and Loi, Shrushma and McAdam, Karen and Hughes-Davies, Luke and Harnett, Adrian N and Ah-See, Mei-Lin and Simcock, Richard and Rea, Daniel and Raj, Sanjay and Woodings, Pamela and Harries, Mark and Howe, Donna and Raynes, Kerry and Higgins, Helen B and Wilcox, Maggie and Plummer, Chris and Mansi, Janine and Gounaris, Ioannis and Mahler–Araujo, Betania and Provenzano, Elena and Chhabra, Anita and Abraham, Jean E and Caldas, Carlos and Hall, Peter S and McCabe, Christopher and Hulme, Claire and Miles, David and Wardley, Andrew M and Cameron, David A and Dunn, Janet A and Agarwal, Roshan and Algurafi, Hafiz and Allerton, Rozenn and Archer, Caroline and Armstrong, Anne and Bale, Catherine and Barraclough, Lisa and Barthakur, Urmila and Bedi, Carolyn and Benstead, Kim and Bloomfield, David and Bowen, Rebecca and Bradley, Chris and Brown, Jane and Butt, Mohammad and Churn, Mark and Cleator, Susan and Cliff, Joanne and Crellin, Perric and Daly, Margaret and De Silva-Minor, Shiroma and Dhadda, Amandeep and Din, Omar and Down, Sue and Eaton, David and Eichholz, Andrew and Epurescu, Daniel and Goh, Chee and Goodman, Andrew and Grieve, Robert and Hadaki, Maher and Harper-Wynne, Catherine and Hayward, Larry and Humphreys, Alison and Innes, Helen and Jafri, Mariam and Jegannathen, Apurna and Kelleher, Muireann and Kristeleit, Hartmut and Lee, Daniela and Lupton, Susan and MacGregor, Carol and Malik, Zafar and Marshall, Jennifer and McGolick, Trevor and Mehra, Rakesh and Mithal, Natasha and Moss, Charlotte and Moss, Aian and Mukesh, Mukesh and Neal, Anthony and Nelmes, Daniel and Neville-Webbe, Helen and Newby, Jacqueline and O'Reilly, Susan and Ostler, Peter and Persic, Mojca and Pettit, Laura and Raja, Fharat and Reed, Catherine and Rigg, Anne and Roe, Helen and Shah, Nihal and Simmonds, Peter and Sims, Eliot and Smith, Sarah and Storey, Nicola and ... and PERSEPHONE Steering Comm & Trial and PERSEPHONE Steering Committee and Trial Investigators
The Lancet, ISSN 0140-6736, 06/2019, Volume 393, Issue 10191, pp. 2599 - 2612
Adjuvant trastuzumab significantly improves outcomes for patients with HER2-positive early breast cancer. The standard treatment duration is 12 months but... 
MEDICINE, GENERAL & INTERNAL | MULTICENTER | THERAPY | HERCEPTIN | RECOMMENDATIONS | CARDIAC EVENTS | FOLLOW-UP | OPEN-LABEL | CHEMOTHERAPY | NEOADJUVANT PERTUZUMAB | PLUS | Breast cancer | Medical research | Toxicity | Research & development--R&D | Medical treatment | Cancer therapies | Survival | ErbB-2 protein | Chemotherapy | Hypotheses | Randomization | Motivation | Technology assessment | Breast | Trastuzumab
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.